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HLA class I and II diversity contributes to the etiologic 
heterogeneity of non-Hodgkin lymphoma subtypes
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Abstract
A growing number of loci within the human leukocyte antigen (HLA) region have been implicated 
in non-Hodgkin lymphoma (NHL) etiology. Here, we test a complementary hypothesis of 
“heterozygote advantage” regarding the role of HLA and NHL, whereby HLA diversity is 
beneficial and homozygous HLA loci are associated with increased disease risk. HLA alleles at 
class I and II loci were imputed from genome-wide association studies (GWAS) using SNP2HLA 
for: 3,617 diffuse large B-cell lymphomas (DLBCL), 2,686 follicular lymphomas (FL), 2,878 
chronic lymphocytic leukemia/small lymphocytic lymphomas (CLL/SLL), 741 marginal zone 
lymphomas (MZL), and 8,753 controls of European descent. Both DLBCL and MZL risk were 
elevated with homozygosity at class I HLA-B and -C loci (OR DLBCL=1.31, 95% CI=1.06–1.60; 
OR MZL=1.45, 95% CI=1.12–1.89) and class II HLA-DRB1 locus (OR DLBCL=2.10, 95% 
CI=1.24–3.55; OR MZL= 2.10, 95% CI=0.99–4.45). Increased FL risk was observed with the 
overall increase in number of homozygous HLA class II loci (p-trend<0.0001, FDR=0.0005). 
These results support a role for HLA zygosity in NHL etiology and suggests that distinct immune 
pathways may underly the etiology of the different NHL subtypes.
INTRODUCTION
Genome-wide association studies (GWAS) have identified a growing list of common 
susceptibility loci modestly associated with risk of non-Hodgkin lymphomas (NHLs) 
including several HLA (human leukocyte antigen) genetic variants on chromosome 6p21, a 
region that is critical for innate and adaptive immune responses. Putative NHL susceptibility 
loci either directly implicate genes within the Major Histocompatibility Complex (MHC) or 
appear in strong linkage disequilibrium (LD) with extended HLA haplotypes (1–5). 
Interestingly, there is little convincing overlap of the identified HLA susceptibility loci 
among the NHL subtypes, diffuse large B-cell lymphoma (DLBCL), follicular lymphoma 
(FL), marginal zone lymphoma (MZL) and chronic lymphocytic leukemia/small 
lymphocytic lymphoma (CLL/SLL), suggesting that disparate aspects of the MHC and 
resulting immune responses are involved in the etiology of each NHL subtype.
The HLA genes are the most polymorphic in the human genome and specific HLA loci 
determine the antigens that are bound by antigen presenting cells (e.g., B cells and dendritic 
cells) and presented to T cells to elicit immune responses. Functionally, HLA molecules are 
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critical for the host immune response. HLA class I molecules present foreign antigens 
primarily to cytotoxic T-cells that in response kill these target cells, while HLA class II 
molecules stimulate antibody production in response to specific antigens.
Reduced diversity, as defined by homozygosity at each co-dominant HLA loci, might 
adversely affect the host’s ability to recognize a more diverse array of foreign antigens and 
thereby increase subsequent disease burden. This concept is supported by a priori research 
that has examined effects of HLA zygosity on infectious disease, whereby a lack of HLA 
class I and II diversity has been associated with increased risk HIV and hepatitis B virus 
infection (6–8).
Given the growing evidence that genetic variation within HLA genes play in the etiology of 
NHL subtypes (1–4, 9), we specifically aimed to test whether lack of HLA diversity - as 
measured by HLA homozygosity – was associated with increased NHL risk. Specifically, we 
posit that associations with HLA Class II, which primarily presents peptides derived from 
extracellular sources, would implicate a role in infectious disease etiology. On the other 
hand, associations with HLA Class I, which primarily presents peptides derived from 
intracellular sources, would suggest a role in related conditions, such as autoimmune or 
atopic conditions. We present here results from a pooled analysis of 25 studies from North 
America, Europe, and Australia where we measured the associations between HLA class I 
and/or class II zygosity and four main NHL subtypes.
MATERIALS AND METHODS
Study sample
Our study sample comprises the same study participants of European descent that were 
included in the original GWAS efforts from which 25 studies participated. Specifically, 
adults diagnosed with incident, non-HIV-related B-cell NHL of mostly European descent, 
ascertained from cancer registries, clinics, or hospitals or through self-report were included 
and where diagnoses were verified by medical and pathology reports (1–4). Study designs 
included prospective cohort studies, population- and hospital-based case-control studies, and 
clinic-based studies. Original details of design methods for each study and of each GWAS 
have been described previously (1–4).
This study was approved by the City of Hope Institutional Review Board. Each participating 
study obtained approval from human subjects review committees and written informed 
consent from all participants. A de-identified pooled dataset with individual-level data on 
genotypes, demographic characteristics, and NHL subtypes of cases was provided by the 
InterLymph Data Coordinating Center (Mayo Clinic, Rochester, MN).
Genotyping
GWAS platforms used include the Illumina 317K, Illumina HumanHap 610K, Illumina 
HumanHap 660W, Illumina Human CNV370-Duo BeadChip, Affymetrix SNP 6.0, and the 
Illumina OmniExpress (Table 1). Quality control metrics employed (e.g., QQ plots and 
Eigenstrat results) and main results of each GWAS have been previously described in-depth 
(1–4).
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HLA imputation
As reported by Skibola et al (2), classical HLA alleles were imputed at HLA class I (HLA-
A, HLA-B, HLA-C) and class II loci (HLA-DQA1, HLA-DQB1, HLA-DRB1, HLA-DPA1, 
HLA-DPB1 ) using SNP2HLA and a reference panel from the Type 1 Diabetes Genetics 
Consortium that comprised 5,225 individuals of European descent who were typed for HLA-
A, B, C, DQA1, DQB1, DRB1, DPA1, DPB1 4 digit alleles. We note that the SNP2HLA 
reference panel is typed both for a panel of MHC SNPs and using classical HLA typing; the 
imputation algorithms used thus rely on both methodologies particularly when only SNPs 
are available. A comparison of imputed HLA alleles to 4-digit HLA sequencing data 
available for a subset of samples showed high concordance: HLA-A (97.3%), B (98.5%), C 
(98.1%) and DRB1 (97.5%). In all, 201 classical HLA alleles (two- and four-digit 
resolution) were successfully imputed (info score r2>0.3 for alleles) and available for 
analysis. Because of the strong LD between the HLA class II A1 and B1 loci (e.g., HLA-
DQA1 and DQB1), we present results for each of the B1 loci (HLA-DQB1, HLA-DRB1, 
HLA-DPB1) since there were fewer homozygous B1 loci than A1 loci. For each HLA locus, 
individuals were coded as homozygote (for any allele) or heterozygote, as determined from 
the imputed alleles. All results presented are based on four-digit resolution.
NHL Classification
NHL subtypes were harmonized at the InterLymph Data Coordinating Center using the 
InterLymph Pathology Working Group guidelines (10,11), which are based on the World 
Health Organization classification (12).
Final analytic sample
Data for HLA loci were directly imputed from the original GWAS SNP panels and evaluated 
for the 3,617 DLBCL, 2,686 FL, 2,878 CLL/SLL, 741 MZL, and 8,753 controls. We note 
that, as with the original GWAS manuscripts, the specific numbers of controls differed by 
NHL subtype, due to different study inclusion and control selection criteria for each NHL 
subtype analyses, as described by the original GWAS publications (enumerated in Table 2).
Statistical analysis
Heterozygosity and homozygosity at each individual HLA locus and the number of 
homozygous loci for class I loci (A, B, C) and class II loci (DQB1, DRB1, DPB1) were 
determined; odds ratios (ORs) and 95% confidence intervals (CIs) were calculated as 
estimates of NHL risk with heterozygotes as the referent category, adjusted for sex, age, 
study, GWAS platform, and ancestry (with principal components as conducted for each 
subtype-specific GWAS and previously published (1–4). For analyses of MZL, adjustment 
by geographic region was conducted due to sample size restrictions (instead of by individual 
study). In addition to calculating the risk estimates for each additional number of 
homozygous loci, we further calculated the p-trend.
To further describe associations of zygosity by loci, we conducted joint effects analyses for 
HLA class I loci and class II loci. Each HLA loci (class I or II) was conducted in a stratified 
manner whereby heterozygotes for all loci were the referent groups and all combinations of 
homozygosity among the loci were evaluated. For example, to pinpoint whether HLA class I 
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associations were attributable to HLA Class I B or C loci, we modeled as one covariate, 4 
levels/combinations for HLA-B and -C (e.g., homozygous for both HLA-B and –C, 
homozygous only for HLA-B, homozygous for only HLA-C, and heterozygous for both), 
with heterozygote for both HLA-B and -C as reference (Table 3). For the associated p-trends 
reported in Table 3, each category is modeled based on ordinal variable in the order listed in 
the table, with heterozygosity at all loci as the referent group in a logistic regression model. 
For each p-trend, we also present the linearized additive relative-risk-per-locus, reflecting 
the slope of the trend-line.
Platform-specific results are shown in a Supplemental Table 1. Additional sensitivity 
analysis included evaluation of potential confounders, including evaluation of associations 
by previously implicated autoimmune conditions and HLA loci associated with specific 
NHL subtypes. We conducted stratified analysis to evaluate whether HLA zygosity 
associations were present among participants with and without autoimmune conditions 
(generally, and by specific conditions); similarly stratified analyses were conducted among 
participants with and without previously identified SNPs associated with NHL subtypes. We 
further calculated the risks, adjusting for autoimmune conditions and for all reported genetic 
susceptibility loci (for each NHL subtype). As neither variable altered the odds ratio >10%, 
those data are not presented. Analyses that restricted studies to population-based controls 
only also did not have measurable effect on the results. Finally, to evaluate the probability 
that some of our results could be due to chance, we used the Benjamini-Hochberg method to 
calculate the false discovery rate (FDR) and applied it to the p-trends as this allows for the 
fewest number of comparisons and thus degrees of freedom to assess the additive model.
Unconditional logistic regression models were applied using SAS 9.4 (SAS Institute). All 
tests of statistical significance were 2-sided.
RESULTS
The numbers of European cases and controls from each of the 25 studies in North America, 
Europe, and Australia for which HLA class I and II loci were evaluated are detailed in Table 
1.
DLBCL
Elevated DLBCL risks of 20–50% were observed for homozygosity for individual HLA 
class I (B and C) and/or class II loci (DRB1 and DQB1) (Table 2). DLBCL risk also 
increased with increasing number of homozygous class I loci (p-trend=0.0008; FDR 
p=0.003) and class II loci (p-trend<0.0001; FDR p=0.0005) (Table 2). Although 
homozygosity for HLA-A had a borderline non-significant effect for increasing DLBCL 
risk, joint analyses suggested that the 30% risk increase observed with two or more 
homozygote loci (Table 2) was attributable to homozygosity at the HLA-B and -C locus 
(OR=1.31, 95% CI=1.06–1.60, Table 3). Similarly, for class II loci, joint analysis showed 
statistically significant associations for homozygosity specifically at the HLA-DRB1 locus 
(OR=2.10, 95% CI=1.24–3.55) as significantly increased risk was observed only in 
combination with homozygous HLA-DRB1 locus (Table 3).
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FL
There were no significant associations between zygosity at HLA class I loci and FL risk 
(Table 2). Statistically significant 24–54% increases, however, were observed for FL risk for 
each of the three HLA class II loci. Further, FL risk increased with the total number of 
homozygous HLA class II loci (p-trend<0.0001; FDR p=0.0005), with an odds ratio of 1.89 
(95% CI=1.37–2.61) for those fully homozygous compared with those fully heterozygous at 
all three HLA class II loci. Joint analyses additionally supported a statistically significant 
increased risk for FL with overall homozygosity at the HLA class II loci (p-trend<0.0001; 
FDR p=0.0005, Table 3).
MZL
Homozygosity at HLA class I loci HLA-B (OR=1.34, 95% CI=1.01–1.78) and –C 
(OR=1.33, 95% CI=1.04–1.70) but not -A (OR=1.06, 95% CI=0.82–1.38) increased MZL 
risk (Table 2). Stratified analysis supported independent associations for both HLA-B and –
C and MZL (Table 3). Homozygosity at HLA class II loci increased MZL risk (Table 2), but 
only the association with HLA-DRB1 reached statistical significance (OR=1.45, 95% 
CI-1.12–1.89, Table 2). Analyses considering single locus homozygosity provided evidence 
of a role for HLA-DRB1 in increasing MZL risk (Table 3).
CLL/SLL
Modest CLL/SLL risk increases were observed for HLA-A (OR=1.19, 95% CI=1.02–1.38), 
HLA-DRB1 (OR=1.19, 95% CI=1.00–1.42) and HLA-DQB1 (OR=1.20, 95% CI=1.03–
1.39) (Table 2). Increasing CLL/SLL risk was not observed with increasing number of 
homozygote class I or class II loci, though when evaluating total numbers of class I and II 
loci altogether, a borderline significant increased risk was observed for those with all five 
homozygote class I and II loci (OR=1.57, 95% CI=1.04–2.38, p-trend = 0.029; FDR=0.055) 
(Table 2). We were unable to isolate CLL/SLL associations with HLA zygosity to any 
singular locus (Table 3).
DISCUSSION
Based on the largest number of NHL subtypes to date for whom imputed HLA data is 
available, we demonstrate that HLA homozygosity plays a role in four B-cell NHL subtypes, 
and that the associations between homozygosity at HLA Class I and/or Class II loci are 
distinct by these subtypes. Specifically, FL risk was associated with homozygosity at HLA 
class II loci, but not Class I loci. CLL/SLL risk appeared to be associated (borderline) with 
homozygosity at either HLA Class I or Class II loci. In contrast, while both DLBCL and 
MZL were associated with zygosity at HLA Class I and Class II loci, the associations 
appeared specific to Class I HLA-B and –C loci and to the Class II HLA-DRB1 locus. We 
note that the p-trends evaluated for each additional homozygous loci remained statistically 
significant after adjust for multiple comparisons, with exception of that for CLL/SLL. Our 
results add to the growing body of literature implicating different roles for HLA class I and 
II loci, key modulators of human immune response, in the heterogeneous etiologies of B-
NHL subtypes (1–4). Our results also add to the current literature which points to 
similarities in the etiologic profiles of DLBCL and MZL (13). Overall, these data support 
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the importance of HLA diversity in NHL etiology, with the type of HLA diversity 
potentially varying by NHL subtype.
The underlying hypothesis regarding the role of HLA zygosity and disease is that 
homozygosity at HLA loci reduces the diversity of peptides that can be presented, with the 
hypothesis that these peptides can reflect etiologic agents such as infectious diseases, self-
antigens for atopic or autoimmune conditions, and even cancerous cells. At present, there is 
a growing body of literature supporting that HLA heterozygotes are more resistant to 
infectious diseases, and the corollary, that HLA homozygotes are more susceptible to 
infectious diseases. Specifically, HLA class I heterozygote advantage (e.g., presenting 
greater diversity of antigenic peptides to CD8+ cytotoxic T lymphocytes) has been 
demonstrated for slowing progression to AIDS (6), whereas heterozygotes at HLA class II 
loci appear to have greater ability in clearing HBV infection (8) and HCV infection (14) 
than homozygotes. HLA-DRB1 heterozygosity has also been reported to confer favorable 
outcome (e.g., against end-stage liver disease) among HCV-infected liver transplant 
recipients (15). There are also reports evaluating HLA zygosity as a key contributor in 
autoimmune conditions. For example, reports of heterozygote advantage for class II loci and 
inflammatory bowel disease (16) and for class I loci and psoriatic arthritis (17) have both 
been published. Specific associations between HLA zygosity and NHL have been limited to 
reports of CLL. Evidence of the importance of HLA zygosity include reports that 
homozygosity at HLA-A, -B, and -DRB1 are associated with CLL (18) and with CLL 
disease progression (19–20), with the hypothesis that limited HLA diversity provided an 
advantage of the tumor to escape the immune response.
HLA heterozygote advantage is posited to work in concert with specific allele associations 
(as opposed to exclusively) (21); our results thus complement ongoing efforts that have 
identified the most role that specific HLA alleles have on NHL subtype risk. In sensitivity 
analysis, we evaluated the effect of known HLA associations and, in stratified and adjusted 
analysis, did not find that these associations diminish the reported association between HLA 
zygosity and NHL subtypes. Further evaluation into how these complementary associations 
act in concert are thus warranted and inclusion of HLA zygosity in the construct of genetic 
risk scores for each NHL subtype should be considered.
Further research to understand the association – or independence - between HLA zygosity 
with infections and autoimmune conditions and NHL risk are also needed (21–24). For 
example, efforts to evaluate autoimmune conditions linked to class II alleles (e.g., Sjögren 
syndrome, systemic lupus erythromatosus, and rheumatoid arthritis) (23) with class II 
zygosity in relation to FL risk could provide potential insight regarding immune mechanisms 
modulating FL risk. A particularly pressing research question is understanding what are the 
underlying mechanisms of individual allele-associations and how are they distinct from 
HLA zygosity associations. Similar efforts to identify commonalities between autoimmune 
and infectious disease associations with HLA loci and zygosity among other NHL subtypes 
are also warranted. Finally, extension of these efforts towards understanding the genetic and 
structural variants and HLA expression are also required to fully understand the implication 
of HLA-allelic associations in the context of overall class I or II zygosity.
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Study strengths include the large sample size available to evaluate individual NHL subtypes 
which no studies have been able to do adequately to date (25). Potential study limitations 
include possible misclassification of HLA alleles due to imputation, although direct 
comparison of a subset with genotyped HLA alleles showed >97% concordance (2). While 
the present analysis leverages the available GWAS data through imputation of HLA alleles, 
we recognize that confirmation with direct HLA allelotyping may provide additional levels 
of information not ascertained in imputed data.
Our study’s restriction to individuals of European ancestry requires our results to be 
replicated for other racial or ethnic groups, as the associations may not apply universally to 
all ethnic groups. However, as demonstrated for HLA associations in autoimmune 
conditions, fine-mapping studies show that the same amino acid changes contribute to 
disease in both European and Asian populations (26), implicating similar underlying 
biologic mechanisms for disease etiology. Studies limitations also include our inability to 
evaluate heterogeneity within NHL subtypes, either defined molecularly, by infectious 
etiology, or by organ site.
In summary, our results add to the growing evidence of HLA alleles as susceptibility loci in 
the etiology of B-cell NHL subtypes. In addition to ongoing fine-mapping studies being 
conducted as follow-up to GWAS, our results here suggest that functional studies aiming to 
understand the underlying biology of zygosity and NHL subtype risk will also be important. 
Additional efforts to evaluate larger-scale zygosity, such as of immune genes and perhaps 
the entire genome may prove important in understanding the full extent of the role diversity 
of the immune response plays in lymphoma etiology.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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